Healthcare active runners: Galena Biopharma Inc (NASDAQ:GALE), Bristol-Myers Squibb (NYSE:BMY), Idera Pharmaceuticals Inc (NASDAQ:IDRA), EXACT Sciences Corporation (NASDAQ:EXAS)

Trade-Ideas LLC identified Galena Biopharma Inc (NASDAQ:GALE) as a “dead cat bounce” (down big yesterday but up big today) candidate. TheStreet Quant Ratings rates Galena Biopharma Inc (NASDAQ:GALE) as a sell. Galena Biopharma Inc (NASDAQ:GALE) stock performance was 12.61% in last session and finished the day at $2.50. Traded volume was 6.16million shares in the last session and the average volume of the stock remained 8.70million shares. The beta of the stock remained 0.82. Galena Biopharma Inc (NASDAQ:GALE) insider ownership is 0.50%.

The 17th annual Oral, Head and Neck Cancer Awareness Week will be held April 20 – 26, 2014. Bristol-Myers Squibb Co (NYSE:BMY) has provided funding for free screenings as part of the company’s support of OHANCAW. Bristol-Myers Squibb Co (NYSE:BMY) rose 0.25 percent to $51.95 Monday on volume of 6.77million shares. The intra-day range of the stock was $51.70 to $52.30. Bristol-Myers Squibb Co (NYSE:BMY) has a market capitalization of $86.08billion.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) shares jumped 17.78% after the company announced positive top-line data from a phase II study on its lead pipeline candidate, IMO-8400, an antagonist of toll-like receptors (TLRs) 7, 8, and 9. Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s stock on Mar 31, 2014 reported a decrease of -10.72% to the closing price of $4.08. Its fifty two weeks range is $0.43 -$6.87. The total market capitalization recorded $336.03million. The overall volume in the last trading session was 6.83million shares. In its share capital, IDRA has 82.36million outstanding shares.

Exact Sciences Corporation (NASDAQ:EXAS) said Thursday afternoon that a U.S. Food and Drug Administration advisory panel has unanimously approved its DNA-based, noninvasive colon cancer screening test, paving the way for potential market approval. On Monday, shares of EXACT Sciences Corporation (NASDAQ:EXAS) advanced 10.19% to close the day at $14.17. Company return on investment (ROI) is -33.50% and its monthly performance is recorded as 5.35%. EXACT Sciences Corporation (NASDAQ:EXAS) quarterly revenue growth is 17.50%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone